US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Aardvark Therapeutics / Equity Capital Markets

<ul>
<li>We believe exercising caution based upon the small market cap of the company and the existing backers is the prudent play at this time.</li>
<li>Aardvark Therapeutics develops novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.</li>
<li>Their lead product candidate is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen and have initiated a Phase 3 trial for hyperphagia associated with PWS.</li>
</ul>


We believe exercising caution based upon the small market cap of the company and the existing backers is the prudent play at this time.
Aardvark Therapeutics develops novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Their lead product candidate is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen and have initiated a Phase 3 trial for hyperphagia associated with PWS.


Aardvark Therapeutics (AARD): Caution Needed Ahead of Small-Cap Obesity Biotech IPO

<ul>
<li>The company set terms for an IPO on Thursday seeking up to $85m if the offering prices at the middle of the ($16-$18) range. </li>
<li>Aardvark Therapeutics develops novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.</li>
<li>Their lead product candidate is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen and have initiated a Phase 3 trial for hyperphagia associated with PWS.</li>
</ul>


The company set terms for an IPO on Thursday seeking up to $85m if the offering prices at the middle of the ($16-$18) range. 
Aardvark Therapeutics develops novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Their lead product candidate is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen and have initiated a Phase 3 trial for hyperphagia associated with PWS.


Aardvark Therapeutics (AARD): Obesity Related Biotech Seeking $85m After Setting Terms for IPO

<ul>
<li>Biotech targeting treatment of obesity and obesity-related conditions, starting with rare hyperphagias filed for its IPO on January 23rd.</li>
<li>Morgan Stanley, BofA Securities, Cantor, RBC Capital are the bookrunners on this IPO.</li>
<li>Lead product, ARD-101 is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which they have initiated a Phase 3 clinical trial for hyperphagia.</li>
</ul>


Biotech targeting treatment of obesity and obesity-related conditions, starting with rare hyperphagias filed for its IPO on January 23rd.
Morgan Stanley, BofA Securities, Cantor, RBC Capital are the bookrunners on this IPO.
Lead product, ARD-101 is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which they have initiated a Phase 3 clinical trial for hyperphagia.


Aardvark Therapeutics (AARD): Peeking at the Prospectus of Another Obesity-Related IPO

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aardvark Therapeutics (AARD US)

Aardvark Therapeutics (AARD): Caution Needed Ahead of Small-Cap Obesity Biotech IPO

Exercising caution with Aardvark Therapeutics due to small market cap and existing backers; developing novel therapeutics for metabolic diseases...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Aardvark Therapeutics (AARD): Caution Needed Ahead of Small-Cap Obesity Biotech IPO

​Exercising caution with Aardvark Therapeutics due to small market cap and existing backers; developing novel therapeutics for metabolic diseases...

IPO Boutique

Aardvark Therapeutics (AARD): Obesity Related Biotech Seeking $85m After Setting Terms for IPO

​Aardvark Therapeutics sets terms for IPO, seeking up to $85m. Developing small-molecule therapeutics for metabolic diseases, with lead product in...

IPO Boutique

Aardvark Therapeutics (AARD): Peeking at the Prospectus of Another Obesity-Related IPO

​Biotech company targeting obesity-related conditions filed for IPO with lead product in Phase 3 clinical trial for rare hyperphagia.

IPO Boutique

Exercising caution with Aardvark Therapeutics due to small market cap and existing backers; developing novel therapeutics for metabolic diseases...

Aardvark Therapeutics sets terms for IPO, seeking up to $85m. Developing small-molecule therapeutics for metabolic diseases, with lead product in...

Biotech company targeting obesity-related conditions filed for IPO with lead product in Phase 3 clinical trial for rare hyperphagia.